

# Women Infertility - Pipeline Review, H2 2020

<https://marketpublishers.com/r/WD02795B1ABEN.html>

Date: September 2020

Pages: 232

Price: US\$ 2,000.00 (Single User License)

ID: WD02795B1ABEN

## Abstracts

Women Infertility - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Pipeline Review, H2 2020, provides an overview of the Women Infertility (Women's Health) pipeline landscape.

Infertility refers to failure to conceive over the course of one full year. Women infertility is caused due to damage of fallopian tubes, ovulation disorders (polycystic ovary syndrome) and endometriosis. Symptoms include abnormal periods, weight gain, back pain, pelvic pain, and cramping. Risk factor of infertility includes smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes medications to stimulate ovulation and hormone therapies.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Women Infertility - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III,

Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 21, 16, 1, 2, 22, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively.

Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:**

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).

The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA)

and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Women Infertility - Overview

Women Infertility - Therapeutics Development

Women Infertility - Therapeutics Assessment

Women Infertility - Companies Involved in Therapeutics Development

Women Infertility - Drug Profiles

Women Infertility - Dormant Projects

Women Infertility - Discontinued Products

Women Infertility - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Women Infertility, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Universities/Institutes, H2 2020  
Number of Products by Stage and Target, H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Women Infertility - Pipeline by Adynxx Inc, H2 2020  
Women Infertility - Pipeline by AlphaMab Co Ltd, H2 2020  
Women Infertility - Pipeline by Amega Biotech, H2 2020  
Women Infertility - Pipeline by Anelleo Inc, H2 2020  
Women Infertility - Pipeline by Aprilbio Co Ltd, H2 2020  
Women Infertility - Pipeline by Aptorum Group Ltd, H2 2020  
Women Infertility - Pipeline by ARTham Therapeutics Inc, H2 2020  
Women Infertility - Dormant Projects, H2 2020  
Women Infertility - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Women Infertility, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Number of Products by Top 10 Targets, H2 2020  
Number of Products by Stage and Top 10 Targets, H2 2020  
Number of Products by Top 10 Mechanism of Actions, H2 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020  
Number of Products by Routes of Administration, H2 2020  
Number of Products by Stage and Routes of Administration, H2 2020  
Number of Products by Top 10 Molecule Types, H2 2020  
Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

Adynxx Inc  
AlphaMab Co Ltd  
Amega Biotech  
Anelleo Inc  
Aprilbio Co Ltd  
Aptorum Group Ltd  
ARTham Therapeutics Inc  
ASKA Pharmaceutical Co Ltd  
Auritec Pharmaceuticals Inc  
Bayer AG  
Beijing Fogangren Bio-Pharm Tech Co Ltd  
Beijing SL Pharmaceutical Co Ltd  
Bharat Serums And Vaccines Ltd  
Bol Pharma  
Bopin (Shanghai) Biomedical Technology Co Ltd  
Chugai Pharmaceutical Co Ltd  
Context Therapeutics LLC  
Daewoong Pharmaceutical Co Ltd  
ElexoPharm GmbH  
Enteris BioPharma Inc  
Eurofarma Laboratorios SA

Evestra Inc  
Evotec SE  
FemmePharma Global Healthcare Inc  
Ferring International Center SA  
Ferring Pharmaceuticals Inc  
Forendo Pharma Ltd  
GeneScience Pharmaceuticals Co Ltd  
Genome & Co  
Glycotope GmbH  
Igenomix SL  
Igyxos SA  
Immunitor Inc  
Isifer AB  
Jiangsu Hengrui Medicine Co Ltd  
Kissei Pharmaceutical Co Ltd  
LG Chem Ltd  
Livzon Pharmaceutical Group Co Ltd  
Luye Pharma Group Ltd  
Mitsubishi Tanabe Pharma Corp  
Myovant Sciences Ltd  
Navad Life Sciences Pte Ltd  
Nippon Shinyaku Co Ltd  
NutriBand Inc  
ObsEva SA  
Oxolife SL  
Pangen Biotech Inc  
Park Active Molecules  
Philogen SpA  
Predictive Therapeutics LLC  
PregLem SA  
Reven Pharmaceuticals Inc  
Richter Gedeon Nyrt  
Shanghai Jing Ze Biotechnology Co Ltd  
Shenzhen Salubris Pharmaceuticals Co Ltd  
Suzhou JiSheng Pharmaceutical Co Ltd  
SYNG Pharmaceuticals Inc  
Takeda Pharmaceutical Co Ltd  
Temple Therapeutics BV  
TiumBio Co Ltd

Trophogen Inc

ValiRx Plc

Viramal Ltd

Xbrane Biopharma AB



## I would like to order

Product name: Women Infertility - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/WD02795B1ABEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/WD02795B1ABEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970